Posts

FURTHER EVIDENCE OF ANXIETY- AND DEPRESSION-LIKE BEHAVIOR FOR TOTAL GENETIC ABLATION OF CANNABINOID RECEPTOR TYPE 1

Authors: Delia Soriano, Alicia Brusco, Laura Caltana Published in Behavioural Brain Research November 2020 Abstract Cannabinoid receptor type 1 (CB1R) is the most abundant cannabinoid receptor in central nervous system. Clinical studies and animal models have shown that the attenuation of endocannabinoid system signaling correlates with the development of psychiatric disorders such as anxiety, depression…

Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure

Authors: J. A. Garza-Cervantes, M. Ramos-González ,O. Lozano, C. Jerjes-Sánchez , and G. García-Rivas Published in Oxidative Medicine and Cellular Longevity October 2020 Abstract A large number of cannabinoids have been discovered that could play a role in mitigating cardiac affections. However, none of them has been as widely studied as cannabidiol (CBD), most likely…

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

Authors: Ester Pagano, Fabio A. Iannotti, Fabiana Piscitelli, Barbara Romano, Giuseppe Lucariello, Tommaso Venneri, Vincenzo Di Marzo, Angelo A. Izzo, Francesca Borrelli Published in Phytotherapy Research September 2020 Abstract Summary Fish oil (FO) and phytocannabinoids have received considerable attention for their intestinal anti‐inflammatory effects. We investigated whether the combination of FO with cannabigerol (CBG) and…

Endocannabinoids Inhibit the Induction of Virulence in Enteric Pathogens

Authors: Melissa Ellermann, Alline R. Pacheco, Angel G. Jimenez, Regan M. Russell, Santiago Cuesta, Aman Kumar, Wenhan Zhu, Gonçalo Vale, Sarah A. Martin, Prithvi Raj, Jeffrey G. McDonald, Sebastian E. Winter, Vanessa Sperandio Published in Cell October 2020 Abstract Summary Endocannabinoids are host-derived lipid hormones that fundamentally impact gastrointestinal (GI) biology. The use of cannabis…

Understanding Cannabis-Based Therapeutics in Sports Medicine

SCC Member Gretchen E. Maurer, DO, MS and colleagues examine the current research potential for cannabis in sports medicine.

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Authors: Gil Bar-Sela, Cohen Idan, Salvatore Campisi-Pinto, Gil M Lewitus Published in Cancers August 2020 Abstract Cannabis or its derivatives are widely used by patients with cancer to help with cancer symptoms and treatment side effects. However, cannabis has potent immunomodulatory properties. To determine if cannabis consumption during immunotherapy affects therapy outcomes, we conducted a…

Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment

Authors: Viola Brugnatelli, Fabio Turco, Ulderico Freo and Gastone Zanette Published in Frontiers in Neuroscience April 2020 Introduction Irritable Bowel Syndrome (IBS) is a functional disorder characterized by abdominal pain, spasms, and altered bowel movements, either predominantly diarrhea (IBS-D), or predominantly constipation (IBS-C), or alternating between those states (Saha, 2014). In the Western world it…

Cannabis Therapeutics and the Future of Neurology

Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience  October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840; Russo, 2017b), who described remarkable successes in treating epilepsy, rheumatic pains, and even universally fatal tetanus with the “new” drug. Cannabis, or “Indian hemp,” was…

Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration

Author: I. Matias, J.W. Wang, A. Schiano Moriello, A. Nieves, D.F. Woodward,V. Di Marzo Published in Science Direct December 2006 Abstract Cannabinoid receptors and the endocannabinoids (anandamide (N-arachidonoylethanolamine—AEA) and 2-arachidonoylglycerol (2-AG)), as well as the AEA congener, palmitoylethanolamide (PEA), are involved in ocular physiology. We measured endocannabinoid and PEA levels by isotope-dilution liquid chromatography-mass spectrometric analysis…

Finding of endocannabinoids in human eye tissues: Implications for glaucoma

Author: June Chen, Isabel Matias, Tim Dinh, Ta Lu, Sonia Venezia, Amelia Nieves, David F. Woodward, Vincenzo Di Marzo Published in Science Direct May 2005 Abstract Cannabinoid CB1 receptors are involved in ocular physiology and may regulate intraocular pressure (IOP). However, endocannabinoid levels in human ocular tissues of cornea, iris, ciliary body, retina, and choroid from…

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid

Authors: Francesca Borrelli, Ester Pagano, Barbara Romano, Stefania Panzera, Francesco Maiello, Diana Coppola, Luciano De Petrocellis, Lorena Buono, Pierangelo Orlando, Angelo A. Izzo Published in Oxford Academic September 2014 Abstract Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid (CB), which interacts with specific targets involved in carcinogenesis. Specifically, CBG potently blocks transient receptor potential (TRP) M8…

Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence

Are phytocannabinoids helpful or harmful for immune competency in the context of the current coronavirus pandemic?